Search Results

(FLASH study)A 12-week treatment, multi-center, randomized, doubleblind,double-dummy, parallel group study to assess the efficacy and safety of switching fromsalmeterol/fluticasone to QVA149 (indacaterolmaleate/glycopyrronium bromide) in symptomatic COPD patients Drug Clinical Trial

Phase 1 Trial of Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus (rAAV2-VMD2-hMERTK) Gene Vector to Patients with Retinal Disease due to MERTK Mutations Drug Clinical Trial

Influenza vaccine (intranasal, live attenuated) (LAIV trivalent): Influenza Virus Type A H1N1, Influenza Virus Type A H3N2, Influenza Virus Type B (Victoria lineage) 107±0.5 FFU Influenza Virus Type B (Victoria lineage) New SFDA Drug Approvals

الهيئة العامة للغذاء والدواء تود التنبيه بأنه تم إيقاف استخدام حشوات مادة الماكرولين(Macrolane) رمز المنتج (في آر إف 20) و ( في آر إف 30 ) التي تحقن تحت الجلد والمستخدمة في عمليات تكبير الثدي من قبل الشركة المصنعة كيو-ميد (Q-Med) حتى إشعار آخر. Warnings

SFDA Withdrawal a Batch for the Profinal Susp 100mg-5ml (110ml) which Produced by the manufacturer JULPHAR duo to Quality Defect Warnings

SFDA Rejects 6.5 Million Kilograms of violating foods from entering the Kingdom during 3 months. Rice comprising25% of the rejected food stuff.. News

A 3 Month, Multicenter, Double-Masked Safety and Efficacy Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients Drug Clinical Trial

A 3 Month, Multicenter, Double-Masked Safety and Efficacy Study of Travoprost Ophthalmic Solution, 0.004% Compared to Timolol (0.5% or 0.25%) in Pediatric Glaucoma Patients Drug Clinical Trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multinational Clinical Study to Evaluate the Efficacy and Safety of 2.0 mg/kg/Week and 2.0 mg/kg/Every Other Week BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) Drug Clinical Trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multinational Clinical Study to Evaluate the Efficacy and Safety of 2.0 mg/kg/Week and 2.0 mg/kg/Every Other Week BMN 110 in Patients With Mucopolysaccharidosis IVA (Morquio A Syndrome) Drug Clinical Trial

Displaying 3121 - 3130 of 3154